Terilyn J. Monroe - 01 Dec 2025 Form 4 Insider Report for Guardant Health, Inc. (GH)

Signature
/s/ John G. Saia, as attorney-in-fact for Tarilyn J. Monroe
Issuer symbol
GH
Transactions as of
01 Dec 2025
Net transactions value
-$4,712,113
Form type
4
Filing time
03 Dec 2025, 21:30:21 UTC
Previous filing
02 Oct 2025
Next filing
05 Jan 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Monroe Terilyn J. Chief People Officer 3100 HANOVER STREET, PALO ALTO /s/ John G. Saia, as attorney-in-fact for Tarilyn J. Monroe 02 Dec 2025 0001652956

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GH Common Stock Options Exercise $704,900 +35,000 +134% $20.14 61,087 01 Dec 2025 Direct
transaction GH Common Stock Options Exercise $429,150 +15,000 +25% $28.61 76,087 01 Dec 2025 Direct
transaction GH Common Stock Sale $1,956,610 -18,576 -24% $105.33 57,511 01 Dec 2025 Direct F1
transaction GH Common Stock Sale $2,544,840 -23,974 -42% $106.15 33,537 01 Dec 2025 Direct F2
transaction GH Common Stock Sale $725,423 -6,786 -20% $106.90 26,751 01 Dec 2025 Direct F3
transaction GH Common Stock Sale $71,612 -664 -2.5% $107.85 26,087 01 Dec 2025 Direct F4
transaction GH Common Stock Sale $202,550 -1,923 -7.4% $105.33 24,164 01 Dec 2025 Direct F5
transaction GH Common Stock Sale $259,504 -2,444 -10% $106.18 21,720 01 Dec 2025 Direct F6
transaction GH Common Stock Sale $85,624 -800 -3.7% $107.03 20,920 01 Dec 2025 Direct F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GH Stock Option (Right to Buy) Options Exercise $0 -35,000 -45% $0.000000 43,204 01 Dec 2025 Common Stock 35,000 $20.14 Direct F8
transaction GH Stock Option (Right to Buy) Options Exercise $0 -15,000 -31% $0.000000 32,627 01 Dec 2025 Common Stock 15,000 $28.61 Direct F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.625 to $105.620. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F2 Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.625 to $106.620. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.625 to $107.560. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $107.730 to $107.970. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.680 to $105.620. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.680 to $106.670. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F7 Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.710 to $107.770. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F8 This represents a stock option granted on February 26, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 2, 2025 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter.
F9 This represents a stock option award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025, and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter.